UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 19 November 2025, London UK
Transfer of Treasury Shares
On 18 November 2025, GSK plc (the "Company")
transferred 22,000,000 ordinary shares of 31¼ pence
each ("Ordinary Shares") that were held by the Company in treasury
("Treasury Shares") to the Company's Jersey resident trust, the
GlaxoSmithKline Employee Trust (the "Jersey Trust"), such Ordinary
Shares to be used to satisfy awards granted under the Company's
Deferred Annual Bonus Plan, Performance Share Plan and Share Value
Plan. The consideration received from
the trustee of the Jersey Trust, of £17.995 per Ordinary Share, was funded by
a loan from GlaxoSmithKline Services Unlimited.
Following the transfer, the Company will hold
234,819,844 Ordinary Shares in treasury and
have 4,080,611,266 Ordinary Shares in issue
(excluding Treasury Shares).
The total number of voting rights in
the Company is 4,080,611,266. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency
Rules.
The Company confirms that, in accordance with DTR 5.5.1R, following
the above transfer the percentage of voting rights attributable to
the Treasury Shares is 5.75%.
This announcement is made in accordance with the requirements of UK
Listing Rule 9.8.2.
Notifications may be sent to [email protected].
V A Whyte
Company Secretary
19 November 2025
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
19, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|